1. Beta-lapachone inhibits proliferation and induces apoptosis in retinoblastoma cell lines.
- Author
-
Shah, H. R., Conway, R. M., Van Quill, K. R., Madigan, M. C., Howard, S. A., Qi, J., Weinberg, V., and O'Brien, J. M.
- Subjects
- *
CELL proliferation , *CANCER cells , *RETINOBLASTOMA , *CELL lines , *ENZYME-linked immunosorbent assay , *RETINA cancer - Abstract
AimsTo investigate the cytotoxicity of beta-lapachone, a potent agent that may selectively target tumour cells, in retinoblastoma (RB) cell lines.MethodsGrowth inhibitory effects of beta-lapachone were evaluated in Y79, WERI-RB1, and RBM human retinoblastoma cell lines. Pro-apoptotic effects of beta-lapachone were evaluated in Y79 cells by detection of caspase 3/7 activity, by enzyme-linked immunosorbent assay for nucleosome fragments, and by cellular morphological analysis.ResultsBeta-lapachone induced significant dose-dependent growth inhibitory effects in all three retinoblastoma cell lines. The 50% growth inhibitory concentration (IC50) of this agent was 1.9 μM in Y79 cells, 1.3 μM in WERI-RB1 cells, and 0.9 μM in RBM cells. Beta-lapachone also induced proapoptotic effects in RB cells. Treatment of Y79 cells with 1.9 μM beta-lapachone (IC50) resulted in a peak, fourfold induction of caspase 3/7 activity at 72 h post-treatment; a peak, 5.6-fold increase in nucleosome fragments at 96 h post-treatment; and a peak, 1.7-fold increase in the frequency of apoptotic cells at 48 h post-treatment, relative to vehicle-treated controls.ConclusionBeta-lapachone induced potent cytotoxic effects in RB cell lines at low micromolar concentrations, suggesting this agent could be useful in the clinical management of RB.Eye (2008) 22, 454–460; doi:10.1038/sj.eye.6702764; published online 16 March 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF